Biopharma Industry Eyes 2025 Bounceback, Grapples With Uncertainty Over Trump Return. More. Reuters. FILE PHOTO: U.S. flag and medicines are seen in this illustration taken, June 27, 2024.

The biopharma sector could grow the state's GDP by $1 billion over the next five years, ... The biopharma industry contributed about $35 billion to the state's GDP in 2022, ...

Bolivia, currently grappling with a measles outbreak, has reported a pharmaceutical industry crisis exacerbated by a dollar ...

Biopharma 4.0, which refers to the digitalization of biomanufacturing processes, aligns with Industry 4.0, a broader movement that dates to 2016, when World Economic Forum founder, Klaus Schwab ...

Biopharma Industry: We Anticipate Tariffs to Bring Short-Term Margin Pressure Direct impact on earnings is likely to be limited for Pfizer, Eli Lilly, Merck, Abbvie and Johnson & Johnson.

Dive into top trends shaping the biopharma industry with STAT and experts, who will share practical insights and forward-looking signals. June 17 - Join us in Boston! Skip to Main Content.

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

The biopharma industry, which discovers, develops, produces, and markets essential medications, has not only revolutionized healthcare but has driven economic growth by creating highly skilled, ...

A pair of lawmakers launched a Life Sciences Caucus Wednesday, adding another layer of Beacon Hill lobbying for the biopharma industry that appears likely to receive a third round of major ...

NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other ...

Click to enlarge. I might be biased here but not for nothing. Ligand's TTM P/E of 8 is cheap as I mentioned. Forward P/E is indeed higher compared to the industry but I think it is still in range.

Morocco’s attempts to rein in high drug prices are facing fierce resistance from pharmaceutical stakeholders, reigniting public anger over inflated costs, persistent shortages, and the lack of ...